Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such as the TRANSCEND-OUTREACH-007 and ZUMA-12 studies successfully advancing into later phases. Although there are currently various approaches to NHL treatment, primarily employing chemotherapy, steroid medication and allogeneic stem cell transplantation, such approaches are not tolerated by all patients and may not achieve complete remissions, creating an opening for immunotherapies to address these challenges. Given the recent FDA approvals of chimeric antigen receptor T-cell (CAR-T) therapies such as idecabtagene vicleucel and lisocabtagene maraleucel, much attention has now turned to the potential of these novel cellular therapies for more effective treatment of NHL.
In this podcast, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Sattva Neelapu of the University of Texas MD Anderson Cancer Center, Houston, TX, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Barbara Savoldo of the University of North Carolina at Chapel Hill, Chapel Hill, NC, Max Mamonkin of the Baylor College of Medicine, Houston, TX, and Susan Prockop of the Memorial Sloan Kettering Cancer Center, New York, NY, discuss the latest clinical updates on T-cell therapies for NHL, highlighting therapies such as lisocabtagene maraleucel and axicabtagene ciloleucel.
iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma
iwAL 2022 Session II: Novel treatment strategies in ALL
The role of the innate immune system in MDS
iwAL 2022 Session I: The standard of care in AML in 2022
iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma
ISA 2022: meeting highlights and recent updates in amyloidosis
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
iwMDS 2022: Key highlights
Identifying high-risk myeloma and improving treatment strategies in these patients
Improving the efficiency of drug approvals in MDS
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
The need for more effective first-line therapies in MDS
Myeloma 2022: day two highlights
The promise of CAR-T therapy in CLL and challenges in the field
Clonal hematopoiesis and pre-MDS states
T-cell engagers in multiple myeloma: current challenges and future outlooks
High-risk MDS: unmet needs and future treatment approaches
The importance of patient-reported outcomes in CAR-T recipients
CAR-T therapy in myeloma and lymphoma
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive